Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06523166 · ClinicalTrials.gov registry record · NA
Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics
A NA study, sponsored by University Hospitals Cleveland Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 320
- Enrollment target
NCT06523166: Recruiting NA study, sponsored by University Hospitals Cleveland Medical Center.
NCT06523166 is a NA study that is actively recruiting participants, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 320 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06523166, a NA study, is actively recruiting participants, sponsored by University Hospitals Cleveland Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 320 participants
- Enrollment target
Study Summary
The current standard of care for patients who underwent left atrial appendage closure (LAAC) is to have follow-up transesophageal echocardiogram (TEE) for device surveillance. TEE is an ultrasound of the heart done by placing a probe in the esophagus under conscious sedation. It does not use contrast but can be cumbersome to patients as it involves placing a probe in the esophagus. Cardiac computerized tomography angiography (cardiac CTA) is a non-invasive imaging modality that involves the use of certain types of x-rays, contrast (dye) and special computers to generate accurate images of the heart. Participants in this study will undergo both TEE and CTA on the same day 90 days after their LAAC procedure. Participants will be in this research study for a period of 1 year, starting from the day of their scheduled LAAC procedure. Participants will undergo a TEE at 90 days after their procedure which is the standard of care imaging study after LAAC. As part of this study, participants will also undergo a cardiac CTA at 90 days as well. Participants will have a routine follow-up visit following device placement as per standard of care as well as a brief phone "check in" at 1 year.
Interventions
- PROCEDURE Transesophageal echocardiography (TEE)
- PROCEDURE Cardiac CTA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What NCT06523166 shows while recruiting
NCT06523166 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Transesophageal echocardiography (TEE) is the first listed.
NCT06523166 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06523166 about?
NCT06523166 is a clinical study titled "Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics". The current standard of care for patients who underwent left atrial appendage closure (LAAC) is to have follow-up transesophageal echocardiogram (TEE) for device surveillance. TEE is an ultrasound of the heart done by placing a probe in the esophagus under conscious sedation. It does not use contras...
What is the current status of trial NCT06523166?
This trial is currently recruiting. It is a NA study. The enrollment target is 320 participants. The study started on 2026-03-27. Estimated completion is 2026-08-31.
What interventions are being tested in trial NCT06523166?
The interventions under investigation include: Transesophageal echocardiography (TEE) (PROCEDURE), Cardiac CTA (PROCEDURE).
Who is sponsoring clinical trial NCT06523166?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06523166's enrollment target sits among peer trials
320 315th of 2000 higher than 1,680 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI